Use of new biologic agents in clinical immunotherapy.
The design of trials with biologic agents must consider the precise definition of the material (which may vary significantly from one laboratory to another), the formulation of the material (which is often complicated by its physical properties), and the safety of the material. To date, efficacy (defined as complete disappearance of tumor) has been seen only in situations associated with direct contact between tumor cells and adjuvant. The assessment of partial efficacy is most difficult because we know little about the basic changes which must be provoked in the immune system to achieve effective immunotherapy. It is only through careful assessment of the immune reaction of patients to their tumors and the correlation of these reactions with clinical response that we can hope to increase our knowledge.
D002986:Clinical Trials as Topic / Q000379:methods* / Q000592:standards; D006801:Humans; D007167:Immunotherapy / Q000592:standards*; D009369:Neoplasms / Q000628:therapy; D014612:Vaccines / Q000276:immunology / Q000592:standards
D014612:Vaccines